1 - 20 of about 63
English: Kono M, Wakisaka R, Komatsuda H, Hayashi R, Kumai T, Yamaki H, Sato R, Nagato T, Ohkuri T, Kosaka A, Ohara K, Kishibe K, Kobayashi H, Hayashi T, Takahara M., Immunotherapy targeting tumor-associated antigen in a mouse model of head and neck cancer. , Head & Neck , vol.Online ahead of print. , 2024 , (IF:2.9)
English: Murai A, Kubo T, Ohkuri T, Yanagawa J, Yajima Y, Kosaka A, Li D, Nagato T, Murata K, Kanaseki T, Tsukahara T, Nagasaki T, Hirohashi Y, Kobayashi H, Torigoe T., NF9 peptide specific cytotoxic T lymphocyte clone cross react to Y453F mutation of SARS-CoV-2 virus spike protein. , Immunological Medicine , vol.Online ahead of print. , 2024 , (IF:4.4)
English: Nagato T, Komatsuda H, Hayashi R, Takahara M, Ujiie N, Kosaka A, Ohkuri T, Oikawa K, Sato R, Wakisaka R, Kono M, Yamaki H, Ohara K, Kumai T, Kishibe K, Katada A, Hayashi T, Kobayashi H., Soluble CD27 as a predictive biomarker for intra-tumoral CD70/CD27 interaction in nasopharyngeal carcinoma. , Cancer Science , vol.Online ahead of print. , 2024 , (IF:5.7)
English: Yajima Y, Kosaka A, Ohkuri T, Hirohashi Y, Li D, Nagasaki T, Nagato T, Torigoe T, Kobayashi H., SARS-CoV-2 spike protein-derived immunogenic peptides that are promiscuously presented by several HLA-class II molecules and their potential for inducing acquired immunity. , Heliyon , vol.9 (9) (p.e20192 - ) , 2023 , (IF:4)
English: Yamaki H, Kono M, Wakisaka R, Komatsuda H, Kumai T, Hayashi R, Sato R, Nagato T, Ohkuri T, Kosaka A, Ohara K, Kishibe K, Takahara M, Hayashi T, Kobayashi H, Katada A., Brachyury-targeted immunotherapy combined with gemcitabine against head and neck cancer. , Cancer Immunology, Immunotherapy , vol.72 (8) (p.2799 - 2812) , 2023 , (IF:6.630)
English: Nagato T, Komatsuda H, Hayashi R, Takahara M, Kishibe K, Yasuda S, Yajima Y, Kosaka A, Ohkuri T, Oikawa K, Harabuchi S, Kono M, Yamaki H, Wakisaka R, Hirata-Nozaki Y, Ohara K, Kumai T, Katada A, Hayashi T, Harabuchi Y, Kobayashi H., Expression of soluble CD27 in extranodal natural killer/T-cell lymphoma, nasal type: potential as a biomarker for diagnosis and CD27/CD70-targeted therapy. , Cancer Immunology, Immunotherapy , vol.72 (7) (p.2087 - 2098) , 2023 , (IF:6.630)
English: Kosaka A, Yajima Y, Yasuda S, Komatsuda H, Nagato T, Oikawa K, Kobayashi H, Ohkuri T., Celecoxib promotes the efficacy of STING-targeted therapy by increasing antitumor CD8+ T-cell functions via modulating glucose metabolism of CD11b+ Ly6G+ cells. , International Journal of Cancer , vol.152 (8) (p.1685 - 1697) , 2023 , (IF:7.316)
English: Komatsuda H, Wakisaka R, Kono M, Kumai T, Hayashi R, Yamaki H, Sato R, Nagato T, Ohkuri T, Kosaka A, Ohara K, Takahara M, Katada A, Kobayashi H., Mitogen-activated protein kinase inhibition augments the T cell response against HOXB7-expressing tumor through human leukocyte antigen upregulation. , Cancer Science , vol.114 (2) (p.399 - 409) , 2023 , (IF:6.518)
English: Xiang H, Toyoshima Y, Shen W, Wang X, Okada N, Kii S, Sugiyama K, Nagato T, Kobayashi H, Ikeo K, Hashimoto S, Tanino M, Taketomi A, Kitamura H., IFN-α/β-mediated NK2R expression is related to the malignancy of colon cancer cells. , Cancer Science , vol.113 (8) (p.2513 - 2525) , 2022 , (IF:6.518)
English: Yajima Y, Kosaka A, Ishibashi K, Yasuda S, Komatsuda H, Nagato T, Oikawa K, Kitada M, Takekawa M, Kumai T, Ohara K, Ohkuri T, Kobayashi H., A tumor metastasis-associated molecule TWIST1 is a favorable target for cancer immunotherapy due to its immunogenicity. , Cancer Science , vol.113 (8) (p.2526 - 2535) , 2022 , (IF:6.518)
English: Kono M, Komatsuda H, Yamaki H, Kumai T, Hayashi R, Wakisaka R, Nagato T, Ohkuri T, Kosaka A, Ohara K, Kishibe K, Takahara M, Katada A, Hayashi T, Kobayashi H, Harabuchi Y., Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma. , Oncoimmunology , vol.11 (1) (p.2021619 - ) , 2022 , (IF:8.110)
English: Kono M, Kumai T, Hayashi R, Yamaki H, Komatsuda H, Wakisaka R, Nagato T, Ohkuri T, Kosaka A, Ohara K, Kishibe K, Takahara M, Katada A, Hayashi T, Celis E, Kobayashi H, Harabuchi Y., Interruption of MDM2 signaling augments MDM2-targeted T cell-based antitumor immunotherapy through antigen-presenting machinery. , Cancer Immunology, Immunotherapy , vol.70 (12) (p.3421 - 3434) , 2021 , (IF:6.968)
English: Kosaka A, Ishibashi K, Nagato T, Kitamura H, Fujiwara Y, Yasuda S, Nagata M, Harabuchi S, Hayashi R, Yajima Y, Ohara K, Kumai T, Aoki N, Komohara Y, Oikawa K, Harabuchi Y, Kitada M, Kobayashi H, Ohkuri T., CD47 blockade enhances the efficacy of intratumoral STING-targeting therapy by activating phagocytes. , Journal of Experimental Medicine , vol.218 (11) (p.e20200792 - ) , 2021 , (IF:14.307)
English: Nagata M, Kosaka A, Yajima Y, Yasuda S, Ohara M, Ohara K, Harabuchi S, Hayashi R, Funakoshi H, Ueda J, Kumai T, Nagato T, Oikawa K, Harabuchi Y, Celis E, Ohkuri T, Kobayashi H., A critical role of STING-triggered tumor-migrating neutrophils for anti-tumor effect of intratumoral cGAMP treatment. , Cancer Immunology, Immunotherapy , vol.70 (8) (p.2301 - 2312) , 2021 , (IF:6.968)
English: Kosaka A, Yajima Y, Hatayama M, Ikuta K, Sasaki T, Hirai N, Yasuda S, Nagata M, Hayashi R, Harabuchi S, Ohara K, Ohara M, Kumai T, Ishibashi K, Hirata-Nozaki Y, Nagato T, Oikawa K, Harabuchi Y, Celis E, Okumura T, Ohsaki Y, Kobayashi H, Ohkuri T., A stealth antigen SPESP1, which is epigenetically silenced in tumors, is a suitable target for cancer immunotherapy. , Cancer Science , vol.112 (7) (p.2705 - 2713) , 2021 , (IF:6.716)
English: Okazaki S, Sasaki T, Yasuda S, Abe M, Yoshida N, Yoshida R, Ishibashi K, Minami Y, Okumura S, Chiba S, Takei H, Hayashi R, Nagato T, Kobayashi H, Sugitani A, Ono Y, Mizukami Y, Kitada M, Ohsaki Y., The feasibility of circulating tumor DNA analysis as a marker of recurrence in triple-negative breast cancer. , Oncology Letters , vol.21 (5) (p.420 - ) , 2021 , (IF:2.967)
English: Hayashi R, Nagato T, Kumai T, Ohara K, Ohara M, Ohkuri T, Hirata-Nozaki Y, Harabuchi S, Kosaka A, Nagata M, Yajima Y, Yasuda S, Oikawa K, Kono M, Kishibe K, Takahara M, Katada A, Hayashi T, Celis E, Harabuchi Y, Kobayashi H., Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma. , Oncoimmunology , vol.10 (1) (p.1856545 - ) , 2020 , (IF:8.110)
English: Nagato T, Takahara M, Harabuchi Y., Ulcerated lesions of the midline gingiva and soft palate. , The American Journal of the Medical Sciences , vol.360 (1) (p.77 - ) , 2020 , (IF:1.962)
English: Ohara M, Ohara K, Kumai T, Ohkuri T, Nagato T, Hirata-Nozaki Y, Kosaka A, Nagata M, Hayashi R, Harabuchi S, Yajima Y, Oikawa K, Harabuchi Y, Sumi Y, Furukawa H, Kobayashi H., Phosphorylated vimentin as an immunotherapeutic target against metastatic colorectal cancer. , Cancer Immunology, Immunotherapy , vol.69 (6) (p.989 - 999) , 2020 , (IF:4.9)
English: Harabuchi S, Kosaka A, Yajima Y, Nagata M, Hayashi R, Kumai T, Ohara K, Nagato T, Oikawa K, Ohara M, Harabuchi Y, Ohkuri T, Kobayashi H., Intratumoral STING activations overcome negative impact of cisplatin on antitumor immunity by inflaming tumor microenvironment in squamous cell carcinoma. , Biochemical and Biophysical Research Communications , vol.552 (2) (p.408 - 414) , 2020 , (IF:2.705)
Copyright (C) 2012～ Asahikawa Medical University, All Rights Reserved.